BioSpace News Archive

AbbVie (NYSE: ABBV) today announced that it has submitted a supplemental New Drug Application (sNDA) for linaclotide (LINZESS®) to the U.S. Food and Drug Administration (FDA) for the treatment of children and adolescents 6 to 17 years of age with functional constipation (FC).

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the approval by the EU-intergovernmental organization EUREKA secretariat of funding for the BRAVE Project (Breaking immune Resistance of Advanced cancers by HERV-K Vaccination and Epigenetic modulation) under the Eurostars-3 program.

Oncocyte Corporation, a precision diagnostics company, announced a reduction in force involving over 40% of Oncocyte’s workforce to realign its team towards key products that address larger markets.

Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is providing an update on its U.S. Phase 2 study evaluating LB1148 for reduction in intra-abdominal adhesions in subjects following elective bowel resection (PROFILE).

On Jan. 26, 2023, the U.S. Food and Drug Administration will hold a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) to consider whether and how the composition for primary doses of the currently available COVID-19 vaccines should be modified and how and whether the composition and schedule for booster doses should be adjusted moving forward.

The global anti-inflammatory therapeutics market size was exhibited at USD 102.37 billion in 2022 and it is expected to hold around USD 127.5 billion by 2030, growing at a CAGR of 4.5% from 2022 to 2030.

The global genomic biomarker market size was exhibited at USD 4.84 billion in 2022 and it is expected to hold around USD 8.6 billion by 2030, growing at a CAGR of 7.46% from 2022 to 2030.

Agilent Technologies Inc. announced that CEO Mike McMullen and CFO Bob McMahon will present at the Goldman Sachs Healthcare CEOs Unscripted Conference and the J.P. Morgan Healthcare Conference.

Y-mAbs Therapeutics, Inc. announced that the European Committee for Medicinal Products for Human use has adopted a negative opinion recommending a refusal of the marketing authorization for omburtamab for the treatment of CNS/leptomeningeal metastasis from neuroblastoma in Europe.

EyePoint Pharmaceuticals, Inc. announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s 2016 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635.